Table 1. Top Plasma Metabolites Associated With Advanced Gastric Lesions and GCa.
| Metabolite | Discovery set | Validation set | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IM/LGIN vs SG/CAG | GC vs SG/CAG | Early GCb vs SG/CAG | IM/LGIN vs SG/CAG | GC vs SG/CAG | Early GCb vs SG/CAG | |||||||||||||||||||||
| No./total No. | OR (95% CI) | P value | FDR | No./total No. | OR (95% CI) | P value | FDR | No./total No. | OR (95% CI) | P value | FDR | No./total No. | OR (95% CI) | P value | No./total No. | OR (95% CI) | P value | No./total No. | OR (95% CI) | P value | ||||||
| sn-2 LysoPC(20:3) | 73/97 | 1.31 (0.93-1.87) | .12 | 0.41 | 30/97 | 0.29 (0.14-0.51) | <.001 | 0.003 | 22/97 | 0.21 (0.08-0.43) | <.001 | 0.01 | 72/80 | 0.58 (1.19-1.21) | .001 | 48/80 | 0.65 (0.45-0.94) | .03 | 31/80 | 0.78 (0.53-1.16) | .15 | |||||
| sn-1 LysoPC(18:3) | 73/97 | 1.26 (0.90-1.77) | .18 | 0.47 | 30/97 | 0.27 (0.13-0.50) | <.001 | 0.003 | 22/97 | 0.26 (0.11-0.51) | <.001 | 0.01 | 72/80 | 0.68 (1.14-1.26) | .02 | 48/80 | 0.62 (0.43-0.88) | .01 | 31/80 | 0.76 (0.51-1.11) | .12 | |||||
| α-Linolenic acid | 73/97 | 1.09 (0.78-1.53) | .62 | 0.84 | 30/97 | 0.37 (0.21-0.62) | <.001 | 0.006 | 22/97 | 0.30 (0.14-0.55) | <.001 | 0.01 | 72/80 | 0.81 (0.80-1.84) | .13 | 48/80 | 0.53 (0.36-0.78) | .003 | 31/80 | 0.62 (0.41-0.92) | .02 | |||||
| Linoleic acid | 73/97 | 1.12 (0.80-1.56) | .51 | 0.76 | 30/97 | 0.43 (0.24-0.72) | .002 | 0.02 | 22/97 | 0.32 (0.15-0.60) | .001 | 0.02 | 72/80 | 0.80 (0.82-1.74) | .11 | 48/80 | 0.56 (0.38-0.81) | .01 | 31/80 | 0.63 (0.42-0.96) | .04 | |||||
| Palmitic acid | 73/97 | 1.23 (0.89-1.71) | .22 | 0.51 | 30/97 | 0.47 (0.26-0.79) | .007 | 0.04 | 22/97 | 0.32 (0.15-0.62) | .002 | 0.02 | 72/80 | 0.70 (1.11-1.30) | .02 | 48/80 | 0.56 (0.38-0.82) | .01 | 31/80 | 0.65 (0.43-0.98) | .04 | |||||
| Arachidonic acid | 73/97 | 1.35 (0.98-1.88) | .07 | 0.41 | 30/97 | 0.51 (0.28-0.85) | .01 | 0.05 | 22/97 | 0.42 (0.20-0.78) | .01 | 0.07 | 72/80 | 0.88 (0.58-2.44) | .22 | 48/80 | 0.70 (0.50-0.99) | .05 | 31/80 | 0.83 (0.57-1.21) | .21 | |||||
Abbreviations: CAG, chronic atrophic gastritis; FDR, false discovery rate; GC, gastric cancer; HGIN, high-grade intraepithelial neoplasia; IM, intestinal metaplasia; LGIN, low-grade intraepithelial neoplasia; LysoPC, lysophosphatidylcholine; OR, odds ratio; SG, superficial gastritis.
a
Individual metabolites associated with GC in the discovery stage (FDR <0.05) and validation stage (P < .05) are shown here. Logistic regression analyses were conducted adjusting for age, sex, and Helicobacter pylori infection. Metabolites are ranked by the P values for GC in the discovery set.
b
We defined participants with HGIN as early GC cases.